🚀 VC round data is live in beta, check it out!
Buchang Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Buchang Pharma and similar public comparables like HUTCHMED (China), ADMA Biologics, Organon, Kalbe Farma and more.
Buchang Pharma Overview
About Buchang Pharma
Shandong Buchang Pharmaceuticals Co Ltd is engaged in research and development, production and sales of Chinese patent medicines.
Founded
2001
HQ
Employees
8.3K
Website
Sectors
Financials (FY)
EV
$3B
Buchang Pharma Financials
Buchang Pharma reported last fiscal year revenue of $2B and EBITDA of $56M.
In the same fiscal year, Buchang Pharma generated $964M in gross profit, $56M in EBITDA, and had net loss of ($81M).
Buchang Pharma P&L
In the most recent fiscal year, Buchang Pharma reported revenue of $2B and EBITDA of $56M.
Buchang Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $964M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 60% | XXX | XXX | XXX |
| EBITDA | — | XXX | $56M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 3% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 7% | XXX | XXX | XXX |
| Net Profit | — | XXX | ($81M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (5%) | XXX | XXX | XXX |
| Net Debt | — | — | $242M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Buchang Pharma Stock Performance
Buchang Pharma has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Buchang Pharma's stock price is $2.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -1.1% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBuchang Pharma Valuation Multiples
Buchang Pharma trades at 1.8x EV/Revenue multiple, and 51.4x EV/EBITDA.
Buchang Pharma Financial Valuation Multiples
As of April 18, 2026, Buchang Pharma has market cap of $3B and EV of $3B.
Equity research analysts estimate Buchang Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Buchang Pharma has a P/E ratio of (31.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 51.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 24.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.0x | XXX | XXX | XXX |
| P/E | — | XXX | (31.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 26.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Buchang Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Buchang Pharma Margins & Growth Rates
Buchang Pharma's revenue in the last fiscal year declined by (17%).
Buchang Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Buchang Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (17%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (65%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Buchang Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Buchang Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| HUTCHMED (China) | XXX | XXX | XXX | XXX | XXX | XXX |
| ADMA Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Organon | XXX | XXX | XXX | XXX | XXX | XXX |
| Kalbe Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| United Laboratories International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Buchang Pharma M&A Activity
Buchang Pharma acquired XXX companies to date.
Last acquisition by Buchang Pharma was on XXXXXXXX, XXXXX. Buchang Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Buchang Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBuchang Pharma Investment Activity
Buchang Pharma invested in XXX companies to date.
Buchang Pharma made its latest investment on XXXXXXXX, XXXXX. Buchang Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Buchang Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Buchang Pharma
| When was Buchang Pharma founded? | Buchang Pharma was founded in 2001. |
| Where is Buchang Pharma headquartered? | Buchang Pharma is headquartered in China. |
| How many employees does Buchang Pharma have? | As of today, Buchang Pharma has over 8K employees. |
| Is Buchang Pharma publicly listed? | Yes, Buchang Pharma is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Buchang Pharma? | Buchang Pharma trades under 603858 ticker. |
| When did Buchang Pharma go public? | Buchang Pharma went public in 2016. |
| Who are competitors of Buchang Pharma? | Buchang Pharma main competitors are HUTCHMED (China), ADMA Biologics, Organon, Kalbe Farma. |
| What is the current market cap of Buchang Pharma? | Buchang Pharma's current market cap is $3B. |
| What is the current revenue of Buchang Pharma? | Buchang Pharma's last fiscal year revenue is $2B. |
| What is the current EV/Revenue multiple of Buchang Pharma? | Current revenue multiple of Buchang Pharma is 1.8x. |
| Is Buchang Pharma profitable? | No, Buchang Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.